Cellectar BioSciences Inc. buy stratec
Zusammenfassung
Diese Einschätzung wurde am 01.07.19 mit einem Endkurs von 18,92 € beendet. Herbe Verluste von -63,76 % verzeichnete die BUY Einschätzung von stratec. stratec hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Cellectar BioSciences Inc. | 0,65 % | 0,65 % | 58,97 % | -72,32 % |
| iShares Core DAX® | -2,93 % | -4,23 % | 9,88 % | 12,47 % |
| iShares Nasdaq 100 | 4,46 % | 8,61 % | 33,06 % | 59,46 % |
| iShares Nikkei 225® | 0,31 % | 0,28 % | 3,87 % | 4,56 % |
| iShares S&P 500 | 2,49 % | 4,77 % | 27,19 % | 50,11 % |
Kommentare von stratec zu dieser Einschätzung
In der Diskussion Cellectar BioSciences Inc. diskutieren
Cellectar signals that its aggressive lymphoma trial is going rather well.
News: CLR announced that it will be expanding patient enrollment in the DLBCL cohort of its ongoing phase 2 trial involving its targeted phospholipid conjugate CLR 131. This announcement comes after the company found that the therapy exceeded the expected response rates, and as such it will be recruiting 30 more patients into the cohort. Expanding enrollment here means that CLRB has an opportunity to get a clearer picture of the efficacy of this radiolabelled drug. Consider this is not the first cohort of patients to be expanded in recruitment, it would seem as though we're getting as
strong an early signal as we can hope for at this stage of study. Still, there is quite a ways to go before we might see approval of this agent, and CLRB will need to find funding to make that happen.